Immune System Connections Map Reveals Therapeutic Opportunities
Researchers create a connectivity map of the human immune system showing how immune cells communicate with each other and ways to modulate these pathways in disease (Source: Disabled World)
Source: Disabled World - August 8, 2022 Category: Disability Tags: Autoimmune Diseases Source Type: news
Deficient RNA Editing Implicated in Inflammatory Disease
Genetic variants that reduce the editing levels of double-stranded RNA are associated with autoimmune and immune-mediated conditions, a study finds. (Source: The Scientist)
Source: The Scientist - August 5, 2022 Category: Science Tags: News & Opinion Source Type: news
Amgen to Acquire Chemocentryx for $4 Billion in Cash
Acquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease
Tavneos Adds to Amgen's Decades-Long Leadership in Inflammation and Nephrology
THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4,... Biopharmaceuticals, Mergers & Acquisitions Amgen, ChemoCentryx, TAVNEOS (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 4, 2022 Category: Pharmaceuticals Source Type: news
Depression, anxiety, substance misuse and self-harm in children and young people with rare chronic liver disease - Chang WH, Foster GR, Kelly DA, Lai AG.
The burden of mental illness in young people with chronic liver disease is not known. In this population cohort study in England, we identified 358 individuals (aged ≤25 years) diagnosed with autoimmune hepatitis or liver disease related to cystic fibros... (Source: SafetyLit)
Source: SafetyLit - August 1, 2022 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
